Head to Head Survey: Baxter International (NYSE:BAX) versus SeaStar Medical (NASDAQ:ICU)

SeaStar Medical (NASDAQ:ICU) and Baxter International (NYSE:BAX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Volatility & Risk

SeaStar Medical has a beta of -1.05, meaning that its stock price is 205% less volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Profitability

This table compares SeaStar Medical and Baxter International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SeaStar Medical	-795.51%	-162.75%	-109.89%
Baxter International	-9.27%	16.57%	5.24%

Earnings and Valuation

This table compares SeaStar Medical and Baxter International”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SeaStar Medical	$1.23 million	12.55	-$12.15 million	($3.91)	-0.90
Baxter International	$11.24 billion	1.06	-$957.00 million	($2.07)	-11.12

SeaStar Medical has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 0.7% of SeaStar Medical shares are owned by company insiders. Comparatively, 0.2% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for SeaStar Medical and Baxter International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SeaStar Medical	1	0	1	0	2.00
Baxter International	2	9	2	0	2.00

SeaStar Medical currently has a consensus target price of $8.00, indicating a potential upside of 128.57%. Baxter International has a consensus target price of $22.45, indicating a potential downside of 2.46%. Given SeaStar Medical’s higher possible upside, research analysts clearly believe SeaStar Medical is more favorable than Baxter International.

Summary

Baxter International beats SeaStar Medical on 8 of the 13 factors compared between the two stocks.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.

About Baxter International

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company’s products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.